Volume | 328,553 |
|
|||||
News | - | ||||||
Day High | 4.37 | Low High |
|||||
Day Low | 3.79 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
T2 Biosystems Inc | TTOO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.79 | 3.79 | 4.37 | 4.21 | 3.90 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
3,489 | 328,553 | US$ 4.22 | US$ 1,384,892 | - | 3.36 - 210.99 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:52 | formt | 200 | US$ 4.06 | USD |
T2 Biosystems Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
17.13M | 4.05M | - | 22.31M | -62.33M | -15.39 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
T2 Biosystems News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TTOO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.92 | 4.37 | 3.36 | 3.73 | 276,813 | 0.14 | 3.57% |
1 Month | 5.42 | 5.75 | 3.36 | 4.39 | 287,357 | -1.36 | -25.09% |
3 Months | 29.11 | 46.85 | 3.36 | 28.68 | 36,564,105 | -25.05 | -86.05% |
6 Months | 13.85 | 70.00 | 3.36 | 26.94 | 74,225,002 | -9.79 | -70.69% |
1 Year | 172.00 | 210.99 | 3.36 | 26.52 | 39,227,812 | -167.94 | -97.64% |
3 Years | 5,800.00 | 18,950.00 | 3.36 | 1,098.62 | 19,167,760 | -5,795.94 | -99.93% |
5 Years | 22,400.00 | 26,900.00 | 3.36 | 1,796.51 | 13,430,461 | -22,395.94 | -99.98% |
T2 Biosystems Description
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease. |